| 148.18 3.02 (2.08%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 179.41 |
1-year : | 187.82 |
| Resists | First : | 153.6 |
Second : | 160.8 |
| Pivot price | 148.27  |
|||
| Supports | First : | 141.94 |
Second : | 118.1 |
| MAs | MA(5) : | 146.01 |
MA(20) : | 150.04 |
| MA(100) : | 124.02 |
MA(250) : | 100.57 |
|
| MACD | MACD : | 0.9 |
Signal : | 2 |
| %K %D | K(14,3) : | 25 |
D(3) : | 21.1 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 160.8 | Low : | 57.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PTGX ] has closed above bottom band by 49.2%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 150.68 - 151.28 | 151.28 - 151.86 |
| Low: | 144.41 - 145.08 | 145.08 - 145.72 |
| Close: | 147.11 - 148.16 | 148.16 - 149.16 |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Fri, 11 Sep 2026
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Thu, 10 Sep 2026
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,048,759.80 in Stock - MarketBeat
Thu, 10 Sep 2026
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares - MarketBeat
Thu, 10 Sep 2026
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Wed, 09 Sep 2026
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript - GuruFocus
Tue, 08 Sep 2026
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 5.289e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 8,290 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 5.988e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 29.3 % |
| Operating Margin | 74.3 % |
| Return on Assets (ttm) | 4.5 % |
| Return on Equity (ttm) | 10.9 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 418.54 |
| Sales Per Share | 1.57536e+008 |
| EBITDA (p.s.) | 1.57536e+008 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 131 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 20.38 |
| Dividend | 0 |
| Forward Dividend | 7.79e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|